Abstract

METHOD DEVELOPMENT AND VALIDATION OF REPAGLINIDE AND VOGLIBOSE IN PURE AND PHARMACEUTICAL DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

Teja Kumar Reddy Konatham*, Narmada Vallakeerthi and Anuradha Masipogu

Abstract

Repaglinide and voglibose are two antidiabetic medicines. Repaglinide is a meglitinide analogue which increases the amount of insulin released by the pancreas. Voglibose is an alpha-glucosidase inhibitor which inhibits the intestinal enzymes that cause breakdown of complex sugars into simple sugars such as glucose. Together, they prevent blood sugar from rising very high after meals. The method was carried out on a Symmetry C18 (150 cm×4.6 mm i.d., 5 μ) column with a mobile phase consisting of Methanol and dihydrogen phosphate buffer (pH 5.0) (60:40 v/v) at a flow rate of 1.5 ml/min. Detection was carried out at 255 nm. The retention time of Repaglinide and voglibose was 5.8 and 3.1 min, respectively. The developed method was validated in terms of accuracy, precision, linearity, limit of detection, limit of quantitation and solution stability. The proposed method can be used for the estimation of these drugs in combined dosage forms.

Keywords: .